title: HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya.
abstract: BACKGROUND
  The altered immune response of persons with human immunodeficiency virus (HIV) infection could result in increased rates of antimalarial treatment failure. We investigated the influence of HIV infection on the response to sulfadoxine-pyrimethamine treatment.
  
  
  METHODS
  Febrile adults with Plasmodium falciparum parasitemia were treated with sulfadoxine-pyrimethamine and were monitored for 28 days. HIV status and CD4 cell count were determined at study enrollment.
  
  
  RESULTS
  Of the adults enrolled in the study, 508 attended all follow-up visits, including 130 HIV-uninfected adults, 256 HIV-infected adults with a high CD4 cell count (> or =200 cells/ micro L), and 122 HIV-infected adults with a low CD4 cell count (<200 cells/ micro L). The hazard of treatment failure at day 28 of follow-up was significantly higher for HIV-infected adults with a low CD4 cell count (20.5%) than for HIV-uninfected adults (7.7%). Anemia (hemoglobin level, <110 g/L) modified the effect of HIV status on treatment failure. When we controlled for fever and parasite density, the hazard of treatment failure for HIV-infected adults with a low CD4 cell count and anemia was 3.4 times higher than that for HIV-uninfected adults (adjusted hazard ratio, 3.38; 95% confidence interval, 1.56-7.34).
  
  
  CONCLUSIONS
  HIV-infected persons with a low CD4 cell count and anemia have an increased risk of antimalarial treatment failure. The response to malaria treatment in HIV-infected persons must be carefully monitored. Proven measures for the control and prevention of malaria must be incorporated into the basic package of services provided by HIV/acquired immunodeficiency syndrome care and treatment programs in malarious areas.
authors.affiliation: Malaria Branch, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. snshah@jhsph.edu
authors.forename: Snehal N
authors.initials: SN
authors.lastname: Shah
authors.forename: Ernest E
authors.initials: EE
authors.lastname: Smith
authors.forename: Charles O
authors.initials: CO
authors.lastname: Obonyo
authors.forename: Kevin C
authors.initials: KC
authors.lastname: Kain
authors.forename: Peter B
authors.initials: PB
authors.lastname: Bloland
authors.forename: Laurence
authors.initials: L
authors.lastname: Slutsker
authors.forename: Mary J
authors.initials: MJ
authors.lastname: Hamel
mesh_terms: D000328:Adult; D000740:Anemia; D000962:Antimalarials / Q000494:pharmacology / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004338:Drug Combinations; D005260:Female; D005334:Fever; D015658:HIV Infections / Q000150:complications* / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D007630:Kenya; D016778:Malaria, Falciparum / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D018512:Parasitemia; D011739:Pyrimethamine / Q000494:pharmacology / Q000627:therapeutic use*; D012008:Recurrence; D013223:Statistics as Topic; D013413:Sulfadoxine / Q000494:pharmacology / Q000627:therapeutic use*; D017211:Treatment Failure
chemical_list: D000962:Antimalarials; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011739:Pyrimethamine